Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:TTHI
CUSIPN/A
Phone+1-416-2607770
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-58.00%
Return on Assets-47.29%
Miscellaneous
EmployeesN/A
Outstanding Shares38,880,000
Market Cap$0.00
Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions
What is Transition Therapeutics' stock symbol?
Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."
How were Transition Therapeutics' earnings last quarter?
Transition Therapeutics Inc (NASDAQ:TTHI) released its quarterly earnings data on Tuesday, September, 15th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.
Has Transition Therapeutics been receiving favorable news coverage?
Media stories about TTHI stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Transition Therapeutics earned a coverage optimism score of 0.21 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Transition Therapeutics.
How do I buy shares of Transition Therapeutics?
Shares of TTHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Transition Therapeutics' stock price today?
One share of TTHI stock can currently be purchased for approximately $1.5248.
How can I contact Transition Therapeutics?
Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.
MarketBeat Community Rating for Transition Therapeutics (NASDAQ TTHI)
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days.
